Compare Repligen Corporation Common Stock (RGEN) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while YieldMax Universe Fund of Option Income ETFs trades at $7.34 (market cap $365.95M). The key difference: Repligen Corporation Common Stock is far larger — about 30.4× YieldMax Universe Fund of Option Income ETFs's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and YieldMax Universe Fund of Option Income ETFs for 57 Days on average.
| RGEN | YMAX | |
|---|---|---|
Market Cap | $11.14B | $365.95M |
Volume | 1,259,263 | 1,000,945 |
Sector | Health | Income / Options Overlay |
52-Week High | $194.57 | $12.60 |
52-Week Low | $102.87 | $7.27 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
YMAX trades at $7.61 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The fund maintains a high distribution policy with weekly dividends, but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues while maintaining the ~40%+ annualized yield.
The outlook remains cautious due to structural concerns about distribution sustainability and NAV erosion. While the high yield attracts income investors, the fund's reverse split potential and stacked fee structure present significant risks. Analyst sentiment is mixed, with some questioning the long-term viability of the current distribution model amid persistent principal decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
